EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Cellectis SA (CLLS) fair value: what the stock is really worth

We calculate from audited financials what Cellectis SA is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US15117K1034

CS Cellectis SA logo Thin data Sep 13, 2026

Cellectis SA

CLLS · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.4250 · Strongly overvalued (−77%)
!Quality 28/100
!Weak Growth (revenue 5y −0.3 %/yr)
!Loss-making · -89.5% net margin (TTM)
!Moderate debt · negative free cash flow
!Trails peers (0/9)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch Cellectis SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$16.26 $0.9700 Fair Value $0.4250 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range $0.9700 – $16.26 · fair‑value band $0.3230 – $0.6375 · the $1.83 price screens above the $0.4250 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

Show more

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Stock analysis

Cellectis SA (CLLS) currently trades at $1.83, while our model-based Fair Value estimate is $0.4250, implying the stock looks roughly 330.7% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.3230 (bear) to $0.6375 (bull), the price of $1.83 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Cellectis SA reported revenue of $72.9M in FY2025 versus $73.9M in FY2021, a compound −0.3%/yr. Reported net income was −$67.6M in FY2025.

Key figures

Market cap $317M · P/S ratio 4.23 · EPS (TTM) $−0.6700 · Net margin −92.7% · Return on equity −76.3% · Return on assets (EBIT) −22.3% · Operating margin −333% · Revenue (TTM) $75.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 67% below its 52-week high and 36% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −77%, CLLS screens richer than that median.

Fair Value models

Bear $0.3230 Fair Value $0.4250 Bull $0.6375
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.5200 $0.7000 $1.05 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.5200 $0.7000 $1.05 54

Open the full fair value analysis →

Notify me when CLLS reaches fair value

Put CLLS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 28/100

Of which business quality 28 · Market factors (momentum, volatility) 7

Profitability 8
Margins and returns on capital today
Quality Growth 60
Are margins and returns improving?
Cashflow 2
Earnings quality: real cash, not paper profit
Fin. Strength 38
Balance sheet, leverage, solvency risk
Investment 85
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 13
Price trend over the last 3–12 months (market factor)
52W Momentum 6
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 2/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+75.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−115.5% (2020) → −45.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CLLS screens 331% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Cellectis SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 648 stocks

Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −85% · Bottom 25%
Profitability
Return on assets −8% · Below median
Net margin (TTM) −90% · Bottom 25%
Growth and dividend
Revenue growth −37% · Bottom 25%
Balance sheet
Debt / equity 0.68× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 4.18× · Priciest 25%
P/S (TTM) 4.23× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)66 · sector 97
DIVIDEND (yield)0 · sector 24

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $515.44 $566.98 +10%
Regeneron Pharmaceuticals, Inc REGN $781.49 $1,241 +59%
argenx SE ARGX $984.39 $917.18 −7%
BeOne Medicines AG 688235 ¥247.30 ¥124.62 −50%
Samsung Biologics Co 207940 1,415,000 KRW 1,556,500 KRW +10%
CSL Limited CSL A$167.10 A$183.81 +10%
Alnylam Pharmaceuticals, Inc ALNY $248.68 $211.88 −15%
Royalty Pharma plc RPRX $58.61 $24.22 −59%
Celltrion, Inc 068270 178,200 KRW 74,519 KRW −58%
BioNTech SE BNTX $96.73 $63.31 −35%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cellectis SA · Fair Value
$0.4250 −331%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Cellectis SA Fair Value". https://www.fairvalue-calculator.com/stock/CLLS

Frequently asked questions

Is Cellectis SA (CLLS) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $0.4250 versus a price of $1.83, about −77% upside (overvalued).
What is the fair value of CLLS?
Our model-based fair value for Cellectis SA is $0.4250 (as of Sep 13, 2026), built from audited fundamentals. The current price: $1.83.
What is the quality score of CLLS?
Cellectis SA has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cellectis SA (CLLS)?
Our model-based price target is the fair value of $0.4250 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario $0.3230, optimistic scenario $0.6375. It is a calculation from audited fundamentals, not an analyst target.
What is the Cellectis SA stock forecast for 2026?
Our models put fair value at $0.4250, about −77% upside versus a price of $1.83 (overvalued). Cautious scenario $0.3230, optimistic scenario $0.6375. The calculation is refreshed regularly with new filings.
What is the revenue of Cellectis SA (CLLS)?
Cellectis SA reported trailing-twelve-month revenue of about $75.1M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Cellectis SA (CLLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cellectis SA it is $0.4250 per share (as of Sep 13, 2026), against a price of $1.83. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Cellectis SA stock overvalued or undervalued in 2026?
As of Sep 13, 2026, CLLS trades above its calculated fair value: price $1.83, fair value $0.4250, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLLS?
No. The price is what the market pays today ($1.83); the fair value is what the company's own numbers justify ($0.4250). For Cellectis SA the two are $1.41 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cellectis SA worth?
The market values Cellectis SA at about $317M (market capitalisation, as of Sep 13, 2026). Per share that is $1.83; our models calculate a fair value of $0.4250 per share.
What do the bullish and bearish scenarios say about CLLS?
Our models span a range for Cellectis SA: cautious scenario $0.3230, base $0.4250, optimistic $0.6375 per share (as of Sep 13, 2026, price $1.83). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cellectis SA (CLLS)?
Balance-sheet figures for Cellectis SA (as of Sep 13, 2026): return on equity −76.3%, debt of 0.68 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is CLLS from its 52-week high?
Cellectis SA trades at $1.83, about 67% below its 52-week high of $5.48 and 36% above the low of $1.35 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4250 is for.
Which stocks are comparable to Cellectis SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cellectis SA stock attractive at the current price?
The data as of Sep 13, 2026: price $1.83, calculated fair value $0.4250 (−77%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLLS calculated?
We run Cellectis SA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.4250, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. Cellectis SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cellectis SA (CLLS)?
The closing price on Sep 14, 2026 was $1.83. Our model-based fair value is $0.4250, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cellectis SA right now?
The price sits above even our optimistic bull case ($0.6375). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3230 to $0.6375) leaves room in how you read the outcome.

Key figures of Cellectis SA

How large is the market capitalisation of Cellectis SA (CLLS)?
The market capitalisation of Cellectis SA is $317M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cellectis SA (CLLS)?
The price-to-sales ratio of Cellectis SA is 4.23 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cellectis SA (CLLS)?
Earnings per share at Cellectis SA are $−0.6700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cellectis SA (CLLS)?
The net margin of Cellectis SA is −92.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cellectis SA (CLLS)?
The return on equity (ROE) of Cellectis SA is −76.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cellectis SA (CLLS)?
On an EBIT basis the return on assets of Cellectis SA is −22.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cellectis SA (CLLS)?
The operating margin of Cellectis SA is −333% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cellectis SA (CLLS)?
Revenue at Cellectis SA is growing −37.3% versus a year earlier (3y avg +56.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cellectis SA (CLLS) generate?
The free cash flow of Cellectis SA is −$42.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cellectis SA (CLLS) carry?
The net debt of Cellectis SA is $56.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cellectis SA in the live analysis

One click puts Cellectis SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.